SCHEMBL6094571

SCHEMBL6094571

CCOC(=O)N1CC2CN(CCCNc3ccc(C#N)cc3)CC2C1

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HRH1 P35367 9/20 0.49
HRH2 P25021 8/20 0.49
HRH3 Q9Y5N1 3/20 0.49
GAA P10253 1/20 0.42
HTR1A P08908 2/20 0.39
DRD4 P21917 2/20 0.39
HTR2A P28223 2/20 0.39
OPRM1 P35372 2/20 0.39
CCR3 P51677 1/20 0.39
USP30 Q70CQ3 1/20 0.39
CACNA1F O60840 1/20 0.39
ADORA3 P0DMS8 1/20 0.39
DRD2 P14416 1/20 0.39
DRD1 P21728 1/20 0.39
DRD5 P21918 1/20 0.39
ADRA1D P25100 1/20 0.39
HTR7 P34969 1/20 0.39
ADRA1A P35348 1/20 0.39
ADRA1B P35368 1/20 0.39
DRD3 P35462 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6093961 0.90 HRH1 (0.43) HRH1HRH2HRH3HTR1ADRD4
SCHEMBL6095760 0.89 HRH1 (0.39) HRH1HRH2HRH3GAAHTR1A
SCHEMBL6093964 0.88 GPR119 (0.43) HRH1HRH2DRD2
SCHEMBL6095414 0.87 HRH1 (0.40) HRH1HRH2HRH3HTR1ADRD4
SCHEMBL6095697 0.87 CCR3 (0.43) HRH1HRH2HRH3CCR3DRD2
SCHEMBL6094707 0.86 HRH2 (0.38) HRH1HRH2HRH3CCR3USP30
SCHEMBL6092576 0.86 HRH1 (0.47) HRH1HRH2HRH3GAAHTR1A
SCHEMBL6094371 0.85 CCR3 (0.41) HRH1HRH2HRH3CCR3DRD2
SCHEMBL6093467 0.85 HRH2 (0.37) HRH1HRH2HRH3CCR3USP30
SCHEMBL6095349 0.85 CCR3 (0.43) HRH1HRH2HRH3CCR3DRD2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7144914-B2 3,7-diazabicyclo[3.3.0]octanes and their use in the treatment of cardiac arrhythmias ASTRAZENECA AB (SE) 2006-12-05 US disclosed
EP-1360187-B1 3,7-DIAZABICYCLO(3.3.0)OCTANES AND THEIR USE IN THE TREATMENT OF CARDIAC ARRHYTHMIAS ASTRAZENECA AB (SE) 2005-06-22 EP disclosed
US-20040053986-A1 3,7-Diazabicyclo[3.3.0]octanes and their use in the treatment of cardiac arrhythmias ASTRAZENECA AB (SE) 2004-03-18 US disclosed
EP-1360187-A1 3,7-DIAZABICYCLO(3.3.0)OCTANES AND THEIR USE IN THE TREATMENT OF CARDIAC ARRHYTHMIAS AstraZeneca AB (SE) 2003-11-12 EP disclosed
WO-2002060902-A1 3,7-DIAZABICYCLO[3.3.0]OCTANES AND THEIR USE IN THE TREATMENT OF CARDIAC ARRHYTHMIAS ASTRAZENECA AB (SE) 2002-08-08 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040053986-A1 3,7-Diazabicyclo[3.3.0]octanes and their use in the treatment of cardiac arrhythmias KCNH1, KCNH2, CACNA1E HRH1 2707/4885HRH2 2122/4885HRH3 3033/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.